2 options
Assessment of alternative treatment strategies for chronic genotype 1 hepatitis C / prepared by Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center, VA Health Economics Resource Center ; principal investigator, Jeremy D. Goldhaber-Fiebert ; investigators, Paul G. Barnett ... [and 5 others] ; research associates, Isomi M. Miake-Lye, Jessica M. Beroes.
- Format:
- Book
- Government document
- Author/Creator:
- Goldhaber-Fiebert, Jeremy D., author.
- Barnett, Paul G. (Paul George), author.
- Language:
- English
- Subjects (All):
- Hepatitis C--Treatment--United States.
- Hepatitis C.
- Antiviral agents--United States.
- Antiviral agents.
- Outcome assessment (Medical care)--United States.
- Outcome assessment (Medical care).
- Hepatitis C, Chronic--therapy.
- Complementary Therapies.
- Genotyping Techniques.
- Outcome Assessment, Health Care.
- Hepatitis C--Treatment.
- United States.
- Medical Subjects:
- Hepatitis C, Chronic--therapy.
- Complementary Therapies.
- Genotyping Techniques.
- Outcome Assessment, Health Care.
- Genre:
- technical reports.
- Technical reports
- Technical reports.
- Physical Description:
- 1 online resource (iii, 37 pages) : illustrations (chiefly color)
- Place of Publication:
- Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, 2013.
- Summary:
- There is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available triple combination therapies that include directly acting antivirals (DAA) along with recently developed patient genotyping (IL-28B) which is predictive of HCV treatment response. Chronic GT1 HCV infections have been historically difficult to treat, with low cure rates on standard two drug therapy (Pegylated Interferon + Ribavirin), high rates of side-effects and treatment discontinuation, and low rates of uptake. Recently, FDA approved two DAAs (boceprevir and telaprevir). Used in combination with standard two drug therapy as triple therapy, these DAAs show higher rates of sustained viral response, though they are also more costly and have more severe side-effect profiles. IL-28B genotyping can help to identify patients least likely to respond to standard therapy and hence who stand to benefit the most from triple therapy and for whom, therefore, the increased risks of side-effects may be most justified.
- Notes:
- "Evidence-based synthesis program."
- "March 2013."
- Includes bibliographical references (pages 29-31).
- Description based on online resource; title from PDF cover (VA, viewed April 16, 2021).
- OCLC:
- 862321793
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.